3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
8
Metastatic Castration-resistant Prostate Cancer
2
Urogenital Neoplasms
1
Prostatic Diseases
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms by Site
1
Neoplasms
1
Male Urogenital Diseases
1
Genital Neoplasms, Male
1
Interventions
Abiraterone Acetate
2
onapristone
1
olaparib
1
gedatolisib
1
darolutamide
1
abiraterone
1
Radiotherapy
1
Pluvicto
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
EPI-506
1
Brachytherapy
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Prostatic Diseases
×
Pluvicto
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled